AbbVie is giving up its patents on a combination drug that is being studied as a coronavirus treatment, becoming the first major drugmaker to drop its rights to make money from a drug that might be used during the pandemic.
艾伯維(AbbVie)將要放棄一種正被研究用于治療新型冠狀病毒的復(fù)合藥物的專利，成為首家對(duì)一種本來有望在大流行病期間暢銷的藥物放棄權(quán)益的大型制藥商。
您已閱讀8%（297字），剩余92%（3381字）包含更多重要信息，訂閱以繼續(xù)探索完整內(nèi)容，并享受更多專屬服務(wù)。